RxDoctor Payments Data

Gary Gehrki, MD

Internal Medicine · Arkadelphia, ARNPI 1295752368

Payments from drug & device makers

$386in general payments, 2019–2025

Across 23 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$107
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$55
  • Lundbeck LLC$37
  • Xeris Pharmaceuticals, Inc.$33
  • Pfizer$28
  • Otsuka America Pharmaceutical, Inc.$18
  • plus $108 from 7 others

What the payments were for

  • Food & beverage$34690%
  • Education$4010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$386 in reported general payments places this provider in the 55th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$70,066
Medicare patients
239
Services billed
1,059

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide248$238,835
JardianceEmpagliflozin131$94,480
MounjaroTirzepatide69$73,264
Cimzia (2 Pack)Certolizumab Pegol12$65,208
EliquisApixaban48$45,979
VraylarCariprazine Hcl26$37,915
RexultiBrexpiprazole22$31,936
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$31,065
LinzessLinaclotide51$28,285
Tresiba Flextouch U-100Insulin Degludec33$14,335
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen559$14,309
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog34$11,821
Divalproex Sodium84$10,974
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$10,149
VascepaIcosapent Ethyl26$9,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Olanzapine$16$77,312130 claims
AbbVieVraylar, Linzess$107$66,20077 claims
PfizerEliquis, Premarin$28$52,09571 claims
Otsuka America Pharmaceutical, Inc.Rexulti$18$31,93622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Arkadelphia

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →